DK0906338T3 - Glukagonlignende peptid-2 analoger - Google Patents

Glukagonlignende peptid-2 analoger

Info

Publication number: DK0906338T3
Authority: DK; Denmark
Prior art keywords: glucagon; analogs; peptide; synthesis; identified
Prior art date: 1996-04-12

Application number

DK97916280T

Other languages

Danish (da)

English (en)

Inventor

Daniel J Drucker

Anna E Crivici

Martin Sumner-Smith

Original Assignee

Ontario Inc 1149336

Allelix Biopharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-12

Filing date

1997-04-11

Publication date

2003-03-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24530501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0906338(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-04-11 Application filed by Ontario Inc 1149336, Allelix Biopharma filed Critical Ontario Inc 1149336

2003-03-03 Application granted granted Critical

2003-03-03 Publication of DK0906338T3 publication Critical patent/DK0906338T3/da

Links

TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 title abstract 2
102000051325 Glucagon Human genes 0.000 abstract 1
108060003199 Glucagon Proteins 0.000 abstract 1
101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 1
102100040918 Pro-glucagon Human genes 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
230000014509 gene expression Effects 0.000 abstract 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
229960004666 glucagon Drugs 0.000 abstract 1
239000003102 growth factor Substances 0.000 abstract 1
230000000968 intestinal effect Effects 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
230000008467 tissue growth Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

DK97916280T 1996-04-12 1997-04-11 Glukagonlignende peptid-2 analoger DK0906338T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US63127396A	1996-04-12	1996-04-12
PCT/CA1997/000252 WO1997039031A1 (en)	1996-04-12	1997-04-11	Glucagon-like peptide-2 analogs

Publications (1)

Publication Number	Publication Date
DK0906338T3 true DK0906338T3 (da)	2003-03-03

Family

ID=24530501

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK97916280T DK0906338T3 (da)	1996-04-12	1997-04-11	Glukagonlignende peptid-2 analoger
DK01129072.3T DK1231219T3 (da)	1996-04-12	1997-04-11	GLucagon-lignende peptid-2 analoger

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK01129072.3T DK1231219T3 (da)	1996-04-12	1997-04-11	GLucagon-lignende peptid-2 analoger

Country Status (16)

Country	Link
EP (5)	EP1231219B1 (zh)
JP (3)	JP4148994B2 (zh)
CN (1)	CN1268640C (zh)
AT (2)	ATE227309T1 (zh)
AU (1)	AU733857B2 (zh)
BR (1)	BRPI9708566B8 (zh)
CA (1)	CA2251576C (zh)
DE (2)	DE69716905T2 (zh)
DK (2)	DK0906338T3 (zh)
ES (2)	ES2188929T3 (zh)
FR (1)	FR13C0013I2 (zh)
HK (3)	HK1033324A1 (zh)
LU (1)	LU92153I2 (zh)
NZ (1)	NZ332281A (zh)
PT (2)	PT906338E (zh)
WO (1)	WO1997039031A1 (zh)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5990077A (en) *	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US5834428A (en)	1995-04-14	1998-11-10	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en)	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
US6852690B1 (en)	1995-08-22	2005-02-08	Amylin Pharmaceuticals, Inc.	Method and composition for enhanced parenteral nutrition
EP1231219B1 (en) *	1996-04-12	2010-08-25	1149336 Ontario Inc.	GLucagon-like peptide-2 analogs
US5952301A (en) *	1996-12-10	1999-09-14	1149336 Ontario Inc.	Compositions and methods for enhancing intestinal function
CA2236519C (en)	1997-05-02	2011-09-13	1149336 Ontario Inc.	Methods of enhancing functioning of the large intestine
DE69819488T2 (de) *	1997-05-16	2004-08-26	1149336 Ontario Inc., Toronto	Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes
WO1999043361A1 (en) *	1998-02-27	1999-09-02	Novo Nordisk A/S	Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
WO1999058144A1 (en) *	1998-05-11	1999-11-18	1149336 Ontario Inc.	Methods of enhancing functioning of the large intestine
GB9930882D0 (en) *	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations
PT1326630E (pt)	2000-09-18	2008-09-02	Sanos Bioscience As	Utilização de péptidos glp-2
US7371721B2 (en)	2000-09-18	2008-05-13	Sanos Bioscience A/S	Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7411039B2 (en)	2002-10-14	2008-08-12	Novo Nordisk A/S	GLP-2 compounds, formulations, and uses thereof
ATE502665T1 (de)	2003-02-04	2011-04-15	Novo Nordisk As	Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
WO2005019262A1 (en) *	2003-08-21	2005-03-03	Novo Nordisk A/S	Purification of glucagon-like peptides
JP4874811B2 (ja)	2004-01-21	2012-02-15	ノボノルディスクヘルスケアアクチェンゲゼルシャフト	ペプチドのトランスグルタミナーゼ媒介性の結合
WO2006050244A2 (en)	2004-11-01	2006-05-11	Nps Allelix Corp.	Treatment of short bowel syndrome patients with colon-in-continuity
ES2361095T5 (es)	2005-05-04	2021-11-23	Zealand Pharma As	Análogos del péptido 2 tipo glucagón (GLP-2)
CN100418983C (zh) *	2005-05-11	2008-09-17	中国药科大学	人胰高血糖素相关肽-2类似物
AU2007319066B2 (en)	2006-11-08	2013-09-19	Zealand Pharma A/S	Selective glucagon-like-peptide-2 (GLP-2) analogues
CN101824087A (zh) *	2009-03-05	2010-09-08	连云港恒邦医药科技有限公司	胰高血糖素样肽-2类似物及其制备方法和用途
EP2311486A1 (en) *	2009-10-07	2011-04-20	Nestec S.A.	GLP-2 for use in intestine and muscle recovery
EP2314616A1 (en) *	2009-10-23	2011-04-27	Ferring B.V.	Peptidic GLP-2 agonists
WO2011052523A1 (ja) *	2009-10-30	2011-05-05	大塚化学株式会社	抗原性ｇｌｐ－１アナログの糖鎖付加体
US9782454B2 (en)	2010-04-22	2017-10-10	Longevity Biotech, Inc.	Highly active polypeptides and methods of making and using the same
JP2013526535A (ja) *	2010-05-11	2013-06-24	エヌピーエスファーマシューティカルズインコーポレイテッド	腎機能障害または肝機能障害の治療または予防のための方法
WO2012131109A2 (en)	2011-04-01	2012-10-04	Max-Planck-Gesellschaft zur Förderung der Wissenschaft e.V.	Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders
CN102924589B (zh) *	2011-08-11	2016-08-24	中肽生化有限公司	胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途
EA028929B1 (ru)	2012-05-03	2018-01-31	Зилэнд Фарма А/С	Аналоги глюкагоноподобного пептида-2 (glp-2)
CN103159848B (zh) *	2013-01-06	2015-11-25	中国人民解放军第四军医大学	人胰高血糖素样肽-2二串体蛋白及其制备方法
US9789164B2 (en)	2013-03-15	2017-10-17	Longevity Biotech, Inc.	Peptides comprising non-natural amino acids and methods of making and using the same
WO2018069442A1 (en) *	2016-10-12	2018-04-19	University Of Copenhagen	Peptide dual agonists of gipr and glp2r
KR102502040B1 (ko)	2016-12-09	2023-02-24	질랜드 파마 에이/에스	아실화 glp-1/glp-2 이중 효능제
WO2019086559A1 (fr)	2017-10-31	2019-05-09	Adocia	Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2020020904A1 (en)	2018-07-23	2020-01-30	Zealand Pharma A/S	Therapeutic uses of glp-2 agonists
EP3628683A1 (en)	2018-09-28	2020-04-01	Zealand Pharma A/S	Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3628682A1 (en)	2018-09-28	2020-04-01	Zealand Pharma A/S	Formulations of glucagon-like-peptide-2 (glp-2) analogues
US20200254065A1 (en)	2019-02-11	2020-08-13	Opko Biologics Ltd.	Long-acting glp-2 analogs
WO2021071837A1 (en)	2019-10-07	2021-04-15	Kallyope, Inc.	Gpr119 agonists
JP2023516187A (ja)	2020-02-28	2023-04-18	キャリーオペ，インク．	Ｇｐｒ４０アゴニスト
EP4126004A1 (en)	2020-03-30	2023-02-08	Zealand Pharma A/S	Agonist combination
CN118843639A (zh) *	2021-12-17	2024-10-25	白南生物技术有限公司	Gipr和glp2r的肽双重激动剂

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5186117A (en)	1975-01-27	1976-07-28	Tanabe Seiyaku Co	Johoseibiryushiseizainoseiho
GB1575343A (en)	1977-05-10	1980-09-17	Ici Ltd	Method for preparing liposome compositions containing biologically active compounds
US4529561A (en)	1978-03-24	1985-07-16	The Regents Of The University Of California	Method for producing liposomes in selected size range
GB2046092B (en)	1979-03-05	1983-11-02	Toyama Chemical Co Ltd	Pharmaceutical composition containing a lysophospholid and a phospholipid
US4452747A (en)	1982-03-22	1984-06-05	Klaus Gersonde	Method of and arrangement for producing lipid vesicles
US4725442A (en)	1983-06-17	1988-02-16	Haynes Duncan H	Microdroplets of water-insoluble drugs and injectable formulations containing same
US5008050A (en)	1984-06-20	1991-04-16	The Liposome Company, Inc.	Extrusion technique for producing unilamellar vesicles
US4921706A (en)	1984-11-20	1990-05-01	Massachusetts Institute Of Technology	Unilamellar lipid vesicles and method for their formation
US4737323A (en)	1986-02-13	1988-04-12	Liposome Technology, Inc.	Liposome extrusion method
US4920016A (en)	1986-12-24	1990-04-24	Linear Technology, Inc.	Liposomes with enhanced circulation time
US5009956A (en)	1987-02-24	1991-04-23	Univ Minnesota	Phospholipase A2-resistant liposomes
US4927637A (en)	1989-01-17	1990-05-22	Liposome Technology, Inc.	Liposome extrusion method
US4944948A (en)	1989-02-24	1990-07-31	Liposome Technology, Inc.	EGF/Liposome gel composition and method
JP2961045B2 (ja)	1993-02-24	1999-10-12	日清製粉株式会社	腸管粘膜増強促進剤
EP0658568A1 (en)	1993-12-09	1995-06-21	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US5990077A (en) *	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
WO1997031943A1 (en)	1996-03-01	1997-09-04	Novo Nordisk A/S	Use of a pharmaceutical composition comprising an appetite-suppressing peptide
EP1231219B1 (en) *	1996-04-12	2010-08-25	1149336 Ontario Inc.	GLucagon-like peptide-2 analogs
US5994500A (en)	1996-07-19	1999-11-30	1149336 Ontario Inc.	Antagonists of intestinotrophic GLP-2 peptides
WO2002066062A2 (en)	2001-02-01	2002-08-29	Drucker Daniel J	Enhancement of glp-2 activity

1997
- 1997-04-11 EP EP01129072A patent/EP1231219B1/en not_active Expired - Lifetime
- 1997-04-11 DK DK97916280T patent/DK0906338T3/da active
- 1997-04-11 PT PT97916280T patent/PT906338E/pt unknown
- 1997-04-11 AU AU25002/97A patent/AU733857B2/en not_active Expired
- 1997-04-11 AT AT97916280T patent/ATE227309T1/de active
- 1997-04-11 JP JP53660897A patent/JP4148994B2/ja not_active Expired - Lifetime
- 1997-04-11 NZ NZ332281A patent/NZ332281A/xx not_active IP Right Cessation
- 1997-04-11 AT AT01129072T patent/ATE478892T1/de active
- 1997-04-11 BR BRPI9708566A patent/BRPI9708566B8/pt active IP Right Grant
- 1997-04-11 ES ES97916280T patent/ES2188929T3/es not_active Expired - Lifetime
- 1997-04-11 EP EP97916280A patent/EP0906338B1/en not_active Expired - Lifetime
- 1997-04-11 EP EP10012937A patent/EP2275438A1/en not_active Withdrawn
- 1997-04-11 CA CA2251576A patent/CA2251576C/en not_active Expired - Lifetime
- 1997-04-11 EP EP08154386A patent/EP2009024A1/en not_active Withdrawn
- 1997-04-11 EP EP10163303.0A patent/EP2218734B1/en not_active Expired - Lifetime
- 1997-04-11 DE DE69716905T patent/DE69716905T2/de not_active Expired - Lifetime
- 1997-04-11 CN CNB971953317A patent/CN1268640C/zh not_active Expired - Lifetime
- 1997-04-11 WO PCT/CA1997/000252 patent/WO1997039031A1/en active IP Right Grant
- 1997-04-11 DK DK01129072.3T patent/DK1231219T3/da active
- 1997-04-11 ES ES01129072T patent/ES2351661T3/es not_active Expired - Lifetime
- 1997-04-11 DE DE60142885T patent/DE60142885D1/de not_active Expired - Lifetime
2000
- 2000-08-15 HK HK00105089A patent/HK1033324A1/xx not_active IP Right Cessation
2001
- 2001-12-07 PT PT01129072T patent/PT1231219E/pt unknown
2003
- 2003-02-07 HK HK11101311.7A patent/HK1147761A1/xx not_active IP Right Cessation
- 2003-02-07 HK HK03100905.1A patent/HK1050204B/zh not_active IP Right Cessation
2007
- 2007-04-24 JP JP2007114302A patent/JP4149497B2/ja not_active Expired - Lifetime
2008
- 2008-02-07 JP JP2008027918A patent/JP5019466B2/ja not_active Expired - Lifetime
2013
- 2013-02-19 LU LU92153C patent/LU92153I2/fr unknown
- 2013-02-22 FR FR13C0013C patent/FR13C0013I2/fr active Active

Also Published As

Publication number	Publication date
BRPI9708566A (pt)	2000-01-04
HK1147761A1 (en)	2011-08-19
AU2500297A (en)	1997-11-07
EP2218734A2 (en)	2010-08-18
JP4148994B2 (ja)	2008-09-10
EP1231219B1 (en)	2010-08-25
EP0906338A1 (en)	1999-04-07
HK1050204B (zh)	2011-09-23
NZ332281A (en)	2000-03-27
EP1231219A1 (en)	2002-08-14
PT906338E (pt)	2003-03-31
LU92153I2 (fr)	2013-04-19
AU733857B2 (en)	2001-05-31
JP5019466B2 (ja)	2012-09-05
EP2218734B1 (en)	2013-06-05
JP2007204491A (ja)	2007-08-16
JP4149497B2 (ja)	2008-09-10
EP0906338B1 (en)	2002-11-06
FR13C0013I1 (zh)	2013-05-04
JP2000511881A (ja)	2000-09-12
PT1231219E (pt)	2010-11-30
ATE478892T1 (de)	2010-09-15
CA2251576C (en)	2012-08-21
BR9708566B1 (pt)	2012-09-04
HK1033324A1 (en)	2001-08-24
CA2251576A1 (en)	1997-10-23
ES2188929T3 (es)	2003-07-01
DE69716905D1 (de)	2002-12-12
EP2009024A1 (en)	2008-12-31
CN1268640C (zh)	2006-08-09
JP2008184465A (ja)	2008-08-14
HK1050204A1 (en)	2003-06-13
WO1997039031A1 (en)	1997-10-23
ES2351661T3 (es)	2011-02-09
FR13C0013I2 (fr)	2013-08-16
DE69716905T2 (de)	2003-07-24
CN1244872A (zh)	2000-02-16
BRPI9708566B8 (pt)	2022-01-18
ATE227309T1 (de)	2002-11-15
DK1231219T3 (da)	2010-12-20
EP2275438A1 (en)	2011-01-19
EP2218734A3 (en)	2010-10-13
DE60142885D1 (de)	2010-10-07

Publication	Publication Date	Title
DK0906338T3 (da)	2003-03-03	Glukagonlignende peptid-2 analoger
NO944644L (no)	1995-06-09	Fremstilling av 3,4,4-trisubstituert-piperidinyl-N-alkylkarboksylater og mellomprodukter
MX9605206A (es)	1997-04-30	1alfa,26-dihidroxi-d-homo-vitamina d3.
TW200716520A (en)	2007-05-01	3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
HUT64298A (en)	1993-12-28	Method for producing 9-amino-7-(substituted)-6-demethyl-6-desoxy-0tetracycline derivatives and medical preparatives containing them
CY1107391T1 (el)	2010-07-28	Αρυλσυμπυκνωμενες αζαπολυκυκλικες ενωσεις
ES2164633T3 (es)	2002-03-01	Genes vegetales sinteticos y procedimiento para su preparacion.
HU902288D0 (en)	1991-07-29	Process for producing new epimers of 1-alpha-hydroxy-d vitamin and their derivatives as well as pharmaceutical preparatives containing these compounds
ES2140858T3 (es)	2000-03-01	Analogos de somatostatina multi-tirosinados.
FI945323A0 (fi)	1994-11-11	5-metyyliuridiinimenetelmä 2',3'-didehydro-3'-deoksitymidiinin (d4T) laajamittaista valmistusta varten
ATE236139T1 (de)	2003-04-15	Verfahren zur herstellung von 2-chlor-5- chlomethyl-thiazol-derivaten
BR9507231A (pt)	1997-09-16	Uso de derivados de ácido carboxílico para a produção de drogas
ES2086065T3 (es)	1996-06-16	Preparacion de tetrahidropiridinas sustituidas.
MY106522A (en)	1995-06-30	Arylaminocarbonyl compounds.
FR2666095B1 (fr)	1994-02-25	Production de la l-lysine par fermentation.
DE59610819D1 (de)	2003-12-18	Arzneistoffe zur selektiven bekämpfung von tumorgewebe
DE3070735D1 (en)	1985-07-11	4-aryloxy-3-phenylpiperidine derivatives, intermediates, a process for the preparation of such compounds and their use as medicaments
DE3862196D1 (de)	1991-05-08	Ein doxorubicinderivat, ein verfahren zu dessen herstellung, pharmazeutische zusammensetzungen und dessen verwendung fuer die herstellung von arzneimitteln.
HU9203928D0 (en)	1993-03-29	6-sulfonyl-substituted 3-hydroxi-chromane derivatives and pharmaceutical preparatives containing them
LU79048A1 (fr)	1979-05-25	Procede d'obtention de composes aminoazo aromatiques a partir d'amines aromatiques via les reactions de diazotation par les vapeurs nitreuses,copulation et rearrangement
SE9203824L (sv)	1993-06-28	Bensofuranylimidazol-derivat, foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande desamma
IL64210A0 (en)	1982-02-28	5-phenyltetrazoles containing basic substituents,a process for their preparation and their use as drugs
MXPA04001856A (es)	2004-06-15	Indan-1-oles c2-sustituidos y sus derivados, metodo para su produccion y su uso como medicamentos.
MXPA04001852A (es)	2004-06-15	Uso de sistemas indan-1-ol c2-sustituidas para la produccion de medicamentos para la profilaxis o tratamiento de obesidad.
ES2129146T3 (es)	1999-06-01	Compuestos citratos alcalino-calcicos y su utilizacion como medicamentos.